Related Experiment Video
Updated: Jun 13, 2026

Assessment of de novo Protein Synthesis Rates in Caenorhabditis elegans
Published on: September 12, 2020
Rapamycin and quasi-programmed aging: four years later
1Roswell Park Cancer Institute, Buffalo, NY, USA. Blagosklonny@oncotarget.com
Abstract:
In 2006, Cell Cycle featured the concept that aging is not caused by molecular damage (nor by free radicals) but instead is a purposeless quasi-program (program-like, but not a program) driven in part by TOR (Target of Rapamycin). Taken together with the analysis of clinical data, this pointed to Sirolimus (rapamycin) as a genuine anti-aging drug which will prolong life in humans and prevent age-related diseases by slowing down aging. Since that time many predictions of this concept have been confirmed. Rapamycin was shown to suppress aging in mammalian cells, prolong life span in mice and flies, improve immunity and stem cell function in old animals, thus confirming twelve predictions as discussed herein. One prediction remains to be confirmed: rapamycin will become the cornerstone of anti-aging therapy in our life time.
Insights
Aging is a quasi-program, not damage, driven by Target of Rapamycin (TOR). Sirolimus (rapamycin) shows potential as an anti-aging drug, prolonging lifespan and improving healthspan by slowing aging processes.
Area of Science:
- Gerontology and molecular biology
- Cellular aging mechanisms
- Pharmacological interventions for aging
Background:
- The concept of aging as a quasi-program, not solely molecular damage, was proposed in 2006.
- Target of Rapamycin (TOR) pathway identified as a key driver of this aging process.
- Sirolimus (rapamycin) emerged as a potential therapeutic agent based on this concept.
Purpose of the Study:
- To evaluate the evidence supporting rapamycin as an anti-aging drug.
- To assess the confirmation of predictions stemming from the quasi-program aging theory.
- To discuss the future role of rapamycin in anti-aging therapy.
Main Methods:
- Review and analysis of existing scientific literature and clinical data.
- Examination of studies investigating rapamycin's effects on aging in various model organisms and cell types.
- Assessment of rapamycin's impact on lifespan, healthspan, immunity, and stem cell function.
Main Results:
- Multiple predictions of the quasi-program aging theory have been experimentally confirmed.
- Rapamycin has demonstrated efficacy in suppressing aging in mammalian cells.
- Studies show rapamycin prolongs lifespan in model organisms and improves health in aged animals.
Conclusions:
- The quasi-program theory of aging is increasingly supported by scientific evidence.
- Rapamycin's multifaceted effects confirm its potential as a significant anti-aging intervention.
- Rapamycin is poised to become a central therapy for age-related diseases and longevity.
More Related Videos
11:58The Replica Set Method: A High-throughput Approach to Quantitatively Measure Caenorhabditis elegans Lifespan
Published on: June 29, 2018
10:39A Suppressor Screen for the Characterization of Genetic Links Regulating Chronological Lifespan in Saccharomyces cerevisiae
Published on: September 17, 2020
Related Concept Videos
Replicative Cell Senescence
Replicative Cell Senescence
Methods of Nuclear Reprogramming
Introduction to Nuclear Reprogramming